12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Iclusig ponatinib regulatory update

The European Commission approved Iclusig ponatinib from Ariad to treat chronic myelogenous leukemia (CML) and Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Iclusig is approved to treat chronic, accelerated or blast phase CML in patients who are resistant to dasatinib or nilotinib, who are intolerant to dasatinib...

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >